Pulse Biosciences (NASDAQ:PLSE) Rating Increased to Hold at Wall Street Zen

Pulse Biosciences (NASDAQ:PLSE) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

PLSE has been the subject of several other research reports. Oppenheimer reiterated an “outperform” rating and set a $30.00 price objective on shares of Pulse Biosciences in a research report on Friday. Mizuho set a $30.00 price target on shares of Pulse Biosciences in a report on Friday, February 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Pulse Biosciences currently has a consensus rating of “Hold” and an average price target of $30.00.

Pulse Biosciences Price Performance

NASDAQ PLSE opened at $21.42 on Friday. Pulse Biosciences has a 1-year low of $12.56 and a 1-year high of $26.30. The business has a 50 day simple moving average of $16.35 and a two-hundred day simple moving average of $16.08. The stock has a market capitalization of $1.45 billion, a PE ratio of -19.83 and a beta of 1.77.

Pulse Biosciences (NASDAQ:PLSE) last posted its earnings results on Thursday, February 19th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.06. The firm had revenue of ($0.09) million for the quarter, compared to the consensus estimate of $0.23 million.

Insider Buying and Selling

In related news, insider Kevin Patrick Danahy sold 20,000 shares of the company’s stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $23.53, for a total transaction of $470,600.00. Following the transaction, the insider directly owned 43,298 shares in the company, valued at approximately $1,018,801.94. This represents a 31.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders have sold 80,000 shares of company stock worth $1,876,200. Corporate insiders own 74.60% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of PLSE. Russell Investments Group Ltd. grew its stake in shares of Pulse Biosciences by 13.8% during the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock valued at $70,000 after buying an additional 619 shares during the last quarter. BNP Paribas Financial Markets grew its position in Pulse Biosciences by 63.6% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after acquiring an additional 680 shares during the last quarter. Alliancebernstein L.P. increased its stake in Pulse Biosciences by 6.7% in the third quarter. Alliancebernstein L.P. now owns 20,620 shares of the company’s stock worth $365,000 after purchasing an additional 1,300 shares during the period. Westside Investment Management Inc. lifted its position in shares of Pulse Biosciences by 2.9% during the fourth quarter. Westside Investment Management Inc. now owns 66,326 shares of the company’s stock worth $911,000 after purchasing an additional 1,886 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in shares of Pulse Biosciences by 275.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after purchasing an additional 2,156 shares during the last quarter. Hedge funds and other institutional investors own 76.95% of the company’s stock.

More Pulse Biosciences News

Here are the key news stories impacting Pulse Biosciences this week:

• Positive Sentiment: Q4 EPS beat analyst expectations — Pulse reported a loss of $0.26 per share vs. consensus -$0.32, beating estimates and showing a smaller-than-expected loss. This helped limit downside after the print. Read More.
• Positive Sentiment: Clinical/business update: company highlighted strong procedural results for its endocardial nPulse catheter (100% freedom from AF at 6 months, 96% procedural success), supporting long‑term product potential and commercialization story. Read More.
• Neutral Sentiment: Investor outreach: Pulse will present at the 46th Annual TD Cowen Healthcare Conference — useful for visibility and investor Q&A but not an immediate revenue driver. Read More.
• Neutral Sentiment: Inducement equity grants: the board awarded equity inducements to two new employees under Nasdaq Rule 5635(c)(4). Standard hiring practice; could be seen as modestly dilutive over time but routine. Read More.
• Negative Sentiment: Revenue missed expectations — reported revenue was effectively flat/negative ($-0.09M) vs. the consensus ~$0.23M, raising near-term commercialization and cash‑flow concerns for some investors. Read More.
• Negative Sentiment: Insider selling: recent filings show insiders sold roughly $0.94M combined in two transactions, which investors may interpret as a negative signal on near‑term insider conviction. Read More. Read More.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.